Cytokines are responsible for the modulation of immunological and inflammatory processes and play a significant role in the pathogenesis of coronary artery disease. We estimated the levels of pro-/anti-inflammatory cytokines in South Indian patients with coronary artery disease. The study population comprised of groups 1–3: 100 patients each with acute myocardial infarction, unstable angina, and stable angina, respectively, and group 4 (100 healthy controls). Cytokine levels (interleukin-6, interleukin-8, interleukin-10, and tumor necrosis factor-α) were estimated by enzyme-linked immunosorbent assay (ELISA). Interleukin-6, interleukin-8, and tumor necrosis factor-α levels were significantly higher in patients from groups 1 and 2, than in group 3 and controls. Acute myocardial infarction patients exhibited higher serum levels of interleukin-10 compared with other groups and control subjects. Patients with unstable angina had significantly lower interleukin-10 concentrations than those with stable angina. The ratios of pro-/anti-inflammatory cytokines in all the study groups increased significantly when patients with unstable angina were compared to other groups. In patients with acute myocardial infarction, interleukin-10 and tumor necrosis factor-α levels showed significant correlation with established risk factors such as body mass index, blood pressure, and lipid levels. Acute myocardial infarction patients show elevation in proinflammatory and anti-inflammatory cytokines, while unstable angina is associated with low levels of serum interleukin-10. Higher levels of antiinflammatory cytokine interleukin-10 may be needed to provide protection in unstable angina. These cytokines are markers of coronary artery disease and may be used for the identification of high-risk patients with unstable angina/acute myocardial infarction.
TziakasD.N., ChalikiasG.K., HatzinikolaouH.I.Anti-inflammatory cytokine profile in acute coronary syndromes: behavior of interleukin-10 in association with serum metalloproteinases and proinflammatory cytokines.Int J Cardiol.2003; 92: 169–175.
2.
MallikaV., GoswamiB., RajappaM.Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Angiology.2007; 58: 513–522.
3.
FusterV., LewisA.Mechanisms leading to myocardial infarction: insights from studies of vascular biology.Circulation.1994; 90: 2126–2146.
4.
RossR.The pathogenesis of atherosclerosis: a perspective for the 1990s.Nature.1993; 362: 801–809.
FusterV., BadimonL., BadimonJ.The pathogenesis of coronary artery disease and acute coronary syndromes.N Engl J Med.1992; 326: 242–250.
7.
ShahP.K.Pathophysiology of unstable angina.Cardiol Clin.1991; 9: 11–26.
8.
El FawalM.A., BergG.A., WheatleyD.J.Sudden coronary death in Glasgow: nature and frequency of acute coronary lesions.Br Heart J.1987; 57: 329–335.
9.
MaseriA.Inflammation, atherosclerosis, and ischemic events—exploring the hidden side of the moon.N Engl J Med.1997; 336: 1014–1016.
10.
MendallM.A., PatelP., BalloonL.C-reactive protein and its relation to cardiovascular risk factors: a population based cross-sectional study.Br J Med.1996; 312: 1061–1065.
11.
RidkerP., CushmanM., StampfelM.J.Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease.Circulation.1998; 97: 425–428.
12.
EnasE.A., YusufS., MehtaJ.Prevalence of coronary artery disease in Asian Indians.Am J Cardiol.1992; 70: 945–949.
13.
MurrayC.J., LopezA.D.Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study.Lancet.1997; 349: 1498–1504.
14.
AchariV., ThakurA.K.Association of major modifiable risk factors among patients with coronary artery disease— a retrospective analysis.J Assoc Physicians India.2004; 52: 103–108.
15.
McKeigueP.M., MillerG.J., MarmotM.G.Coronary artery disease in South Asians overseas: a review.J Clin Epidemiol.1989; 41: 597–598.
16.
BegomR., SinghR.B.Prevalence of coronary artery disease and risk factors in urban population of south and north India.Acta Cardiol.1995; 3: 227–240.
17.
DaviesM.J.Reactive oxygen species, metalloproteinases, and plaque stability.Circulation.1998; 97: 2382–2383.
18.
KaiH., IkedaH., YasukawaH.Peripheral blood levels of matrix metalloproteinases are elevated in patients with acute coronary syndromes.J Am Coll Cardiol.1998; 32: 368–372.
19.
KimS.H., LeeW.H., KwonB.S.Tumor necrosis factor receptor superfamily may destabilize atherosclerotic plaques by inducing matrix metalloproteinases.Jpn Circ J.2001; 65: 136–138.
20.
KaartinenM., van der WalA.C., van der LoosC.M.Mast cell infiltration in acute coronary syndromes: implications for plaque rupture.J Am Coll Cardiol.1998; 32: 606–612.
21.
MallatZ., CorbazA., ScoazeeA.Expression of IL-18 in human atherosclerotic plaques and relation to plaque instability.Circulation.2001; 104: 1598–1603.
22.
ShahP.K., FalkE., BadimonJ.J.Human macrophages induce breakdown of collagen in fibrous caps of atherosclerotic plaques. Potential role of matrix degrading metalloproteinases and implications for plaque rupture.J Am Coll Cardiol.1998; 32: 606–612.
23.
LiJ., GuoY., YangY.Enhancing anti-inflammatory cytokine IL-10 may be beneficial for acute coronary syndrome.Med Hypotheses.2005; 65: 103–106.
24.
LacrazS., NicodL.P., ChicheporticheR.IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes.J Clin Invest.1995; 96: 2304–2310.
25.
MallatZ., BenardS., DurieZ.M.Protective role of interleukin-10 in atherosclerosis.Circ Res.1999; 85: 17–24.
26.
RajappaM., SharmaA.An update on biomarkers of cardiac injury—a review.Angiology.2005; 56: 677–691.
27.
RajappaM., SridharM.G., BalachanderJ.Lipoprotein (a) and comprehensive lipid tetrad index as a marker for coronary artery disease in NIDDM patients in south India.Clin Chim Acta.2006; 372: 70–75.
28.
SharmaA., RajappaM., SaxenaA.Cytokine profile in Indian females with cervical intraepithelial neoplasia and cancer cervix.Int J Gynecol Cancer.2007; 17: 879–885.
29.
CortiR., FusterV., BadimonJ.J.Pathogenic concepts of acute coronary syndromes.J Am Coll Cardiol.2003; 41: 7S–14S.
30.
HajjarD.P., HaberlandM.E.Lipoprotein trafficking in vascular cells: molecular Trojan horses and cellular saboteurs.J Biol Chem.1997; 272: 22975–22978.
31.
PaolettiR., GottoAMJr., HajjarD.P.Inflammation in atherosclerosis and implications for therapy.Circulation.2004; 109(23 Suppl 1): III20–III26.
32.
OrenH., ErbayA.R., BalciM.Role of novel biomarkers of inflammation in patients with stable coronary heart disease.Angiology.2007; 58: 148–155.
33.
OtakeH., ShiteJ., ShinkeT.Relation between plasma adiponectin, high-sensitivity C-reactive protein, and coronary plaque components in patients with acute coronary syndrome.Am J Cardiol.2008; 101: 1–7.
34.
RidkerP.M.Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity.Nutr Rev.2007; 65: S253–S259.
WaehreR., HalvorsenB., DamasJ.K.Inflammatory imbalance between IL-10 and TNF alpha in unstable angina: potential plaque stabilizing effects of IL-10.Eur J Clin Invest.2002; 32: 803–810.
37.
PasquiA.L., Di RenzoM., BovaG.Proinflammatory/anti-inflammatory cytokine imbalance in acute coronary syndromes.Clin Exp Med.2006; 6: 38–44.
38.
SmithD.A., IrvingS.D., SheldonJ.Serum levels of the anti-inflammatory cytokine interleukin-10 are decreased in patients with unstable angina.Circulation.2001; 104: 746–749.
39.
Mizia-StecK., GasiorZ., Zahorska-MarkiewiczB.Serum tumor necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes.Coron Artery Dis.2003; 14: 431–438.
40.
ShibataM., EndoS., ImadaK.Elevated levels of interleukin-1 receptor antagonist and interleukin-10 in patients with acute myocardial infarction.J Interferon Cytokine Res.1997; 17: 145–150.
41.
SzodoraylP., TimarO., VeresK.Th1/Th2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines-immunological alterations in acute coronary syndrome and stable coronary artery disease.Scand J Immunol.2006; 64: 336–344.
42.
WangP., WuP., SiegelM.I.Interleukin-10 inhibits nuclear factors-κβ (NF-κβ) activation in human monocytes.J Biol Chem.1995; 270: 9558–9563.
43.
LentschA.B., ShanleyT.P., SharmaV.In vivo suppression of NF-κβ and preservation of 1KB by interleukin-10 and interleukin-13.J Clin Invest.1997; 100: 2443–2448.
44.
MertzP.M., DewittD.L., StetlerstevensonW.G.Interleukin-10 suppression of monocyte prostaglandin-H synthase-2: mechanism of prostaglandin-dependent matrix metalloproteinase production.J Biol Chem.1994; 269: 21322–21329.
45.
AraiT., HiromatsuK., NishimuraH.Endogenous IL-10 prevents apoptosis in macrophages during salmonella infection.Biochem Biophys Res Commun.1995; 213: 600–607.
46.
CohenS.B., CrawleyJ.B., MohanM.C.Interleukin-10 rescues cells from apoptotic cell death: association with an upregulation of Bcl-2.Immunology.1997; 92: 1–5.
47.
XangZ., ZingerelliB., SzaboC.Crucial role of endogenous interleukin production in myocardial ischemia/reperfusion injury.Circulation.2000; 101: 1019–1026.
SilvestreJ., MallatZ., DuriezM.Anti-angiogenic effect of interleukin-10 in ischemia-induced angiogenesis in mice hindlimb.Circ Res.2000; 87: 448–452.
50.
LuoY., JiangD., WenD.Changes in serum interleukin-6 and C-reactive protein levels in patients with acute coronary syndromes.Heart Vessels.2004; 19: 257–262.
51.
BalbayY., TikizH., BaptisteR.J.Circulating IL-1 beta, IL-6, TNF-alpha and soluble ICAM-1 in patients with acute coronary syndromes.Angiology.2001; 52: 109–114.
52.
KoukkunenH., PenttilaK., KemppainenA.C-reactive protein, fibrinogen, IL-6, and TNF-alpha in the prognostic classification of unstable angina pectoris.Ann Med.2001; 33: 37–47.
53.
WangY.N., CheS.M., MaH.Q.Clinical significance of IL-1 beta, sIL-2R, IL-6, TNF-alpha and IFN-gamma in acute coronary syndromes.Chin Med Sci J.2004; 19: 120–124.
54.
FinkelM., OddisC.V., JacobT.D.Negative inotropic effects of cytokines on the heart mediated by nitric oxide.Science.1992; 257: 387–389.
55.
TousoulisD., DaviesG., StefanadisC.Inflammatory and thrombotic mechanisms in coronary atherosclerosis.Heart.2003; 89: 993–997.
56.
BrueckmannM., BertschT., LangS.Time course of systemic markers of inflammation in patients presenting with acute coronary syndromes.Clin Chem Lab Med.2004; 42: 1132–1139.
57.
PinderskiO.L.J., HedrickC.C., OlveraT.Interleukin-10 blocks atherosclerotic events in vitro and in vivo.Arterioscler Thromb Vasc Biol.1999; 19: 2847–2853.
58.
TarkeltaubR.A.IL-10 an immunological scalpel for atherosclerosis.Arterioscler Thromb Vasc Biol.1999; 19: 2823–2825.
59.
DurringtonP.N.Triglycerides are more important than epidemiology has suggested.Atherosclerosis.1998; 141(suppl 1): S57–S62.
